Values First Advisors Inc. Has $3.60 Million Holdings in Emergent BioSolutions Inc. (NYSE:EBS)

Values First Advisors Inc. reduced its position in shares of Emergent BioSolutions Inc. (NYSE:EBS) by 17.4% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 376,692 shares of the biopharmaceutical company’s stock after selling 79,516 shares during the quarter. Emergent BioSolutions makes up about 2.0% of Values First Advisors Inc.’s holdings, making the stock its 8th biggest holding. Values First Advisors Inc. owned about 0.70% of Emergent BioSolutions worth $3,601,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Stifel Financial Corp purchased a new position in Emergent BioSolutions during the 3rd quarter valued at $96,000. FORA Capital LLC purchased a new position in Emergent BioSolutions during the 3rd quarter valued at $103,000. Landscape Capital Management L.L.C. purchased a new position in Emergent BioSolutions during the 3rd quarter valued at $141,000. Entropy Technologies LP purchased a new position in Emergent BioSolutions during the 3rd quarter valued at $155,000. Finally, PFG Investments LLC purchased a new position in Emergent BioSolutions during the 3rd quarter valued at $228,000. 78.40% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have issued reports on EBS. StockNews.com downgraded shares of Emergent BioSolutions from a “buy” rating to a “hold” rating in a research report on Friday, January 24th. HC Wainwright reissued a “buy” rating and set a $15.00 price objective on shares of Emergent BioSolutions in a research report on Tuesday, January 21st. Finally, Benchmark boosted their price objective on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the company a “buy” rating in a research report on Thursday, November 7th.

Emergent BioSolutions Price Performance

NYSE:EBS opened at $9.66 on Wednesday. The firm’s 50-day moving average price is $9.66 and its 200-day moving average price is $9.23. The company has a quick ratio of 1.47, a current ratio of 2.88 and a debt-to-equity ratio of 1.30. Emergent BioSolutions Inc. has a 1-year low of $1.48 and a 1-year high of $15.10.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.